Latest Recruitment News

Hiremii Limited reported a 4.4% revenue increase in Q4 FY25 alongside positive operating cash flow, while accelerating commercialisation of its proprietary AI recruitment platform and expanding through a key acquisition.

Karoon Energy announces CEO Dr Julian Fowles will depart by mid-2026 as the company relocates key corporate roles to Brazil and the USA, initiating a global search for a Houston-based successor.

Alligator Energy reports a 10% increase in indicated uranium resources at its Samphire Project, secures a $17.25 million capital raise, and announces a CEO transition as it advances key uranium exploration and development milestones.

Race Oncology has safely treated the first patient with its RC220 drug alone and in combination with doxorubicin in a Phase 1 trial, while bolstering its clinical leadership and maintaining a strong cash position to fund operations through 2026.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase to $204 million in Q2 2025, launched its new prostate cancer imaging agent Gozellix in the U.S., and advanced key clinical trials despite an ongoing SEC inquiry.

InhaleRx Limited has secured key ethics approvals and initiated manufacturing for its inhaled drug candidates targeting breakthrough cancer pain and panic disorder, supported by a $38.5 million funding facility to accelerate development.

Cleo Diagnostics reports steady progress in its ovarian cancer diagnostic test development, with clinical trial recruitment on track and strategic access to major biobanks enhancing its regulatory pathway.

Aurelia Metals has successfully met its FY25 production and cost guidance, while advancing key mining projects and maintaining a robust cash position of $110 million.

Tryptamine Therapeutics has begun recruiting patients for a pioneering clinical trial testing IV-infused psilocin combined with psychotherapy to treat Binge Eating Disorder, aiming to deliver faster and more controlled treatment outcomes.

Adherium Limited has successfully completed a $4.49 million entitlement offer, combining institutional and retail components, to fund expansion of its Hailie® digital respiratory monitoring platform.

Clarity Pharmaceuticals has successfully completed recruitment for its pivotal Co-PSMA Phase II trial, testing its novel Cu-SAR-bisPSMA diagnostic against the current standard in detecting prostate cancer recurrence. This milestone advances their mission to improve early detection and treatment outcomes for men with low PSA levels.

Prescient Therapeutics has initiated its first US clinical site for the PTX-100 Phase 2a trial targeting Cutaneous T-Cell Lymphoma, marking a key milestone in expanding patient recruitment beyond Australia.